http://news.excite.com/news/bw/011011/ri-milkhaus-laboratory
Thu, Oct 11 9:43 AM EDT
PROVIDENCE, R.I. (BW HealthWire)
- Milkhaus Laboratory, Inc, a clinical stage biopharmaceutical company,
announced today that it had been granted a patent for the therapeutic use
of antibodies at concentrations significantly below those currently employed
in the treatment of disease.
The conventional therapeutic application
of antibodies involves their use in concentrations which cause a specific
antibody to combine with a target antigen to render it inoperable, non-infectious
or to neutralize it. More recently, antibodies have been used as vaccines
to induce specific immune responses. Antibody therapy is in increasing
use today for a variety of indications including immune system deficiency
disorders, infections such as hepatitis, and as anti-cancer agents which
target specific tumor antigens.
"The implications of this patent
are very far reaching. Our work suggests that this invention, one which
employs antibodies in low concentrations, involves a molecular signal that
ultimately induces a therapeutic response similar to that observed in traditional
antibody therapy," said Dr. John McMichael, the Company's founder and CEO.
"Our immediate work will be focused on diabetes. However, experience suggests
that the technology will be useful in treating a variety of diseases including
multiple sclerosis, autism, attention deficit disorder ("ADD"), pulmonary
disorders, Alzheimer's Disease and Crohn's Disease," he added.
Milkhaus Laboratory, Inc. is a privately
held biopharmaceutical Company focused on the development of therapeutic
agents for chronic diseases in man and animals. It has completed successful
clinical trials with two of its products: ML-03 in Phase II trials for
COPD, bronchitis and cystic fibrosis, and ML-04 in a Phase II evaluation
for benign prostatic hyperplasia, or "BPH." Phase II studies of the Company's
products for prostatitis and otitis media are scheduled to begin shortly.
©2001 At Home Corporation